ArticleScientific reports2025
miR-340 reverses chemotherapy resistance in colon cancer via the PDCD4/WNT/β-catenin signalling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Screening Biomarkers Related to Circadian Rhythm of Gastric Cancer Through Bioinformatics.Applied biochemistry and biotechnology · 2026Article
- The prognostic value of miR-363-5p in colorectal cancer and its associated molecular mechanisms.Hereditas · 2026Article
- Study of ß-catenin signaling pathway modulated by PTHrP in cell and animal colorectal cancer models.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The silencing of miR-340 has been implicated in the progression and migratory capacity of colorectal cancer (CRC); however, its role in modulating oxaliplatin-induced chemotherapy resistance in CRC remains largely unexplored. In this study, we investigated the influence of miR-340 on oxaliplatin resistance in CRC and elucidated the underlying molecular mechanisms. Oxaliplatin-resistant HCT116 (HCT116-OxR) and CT26 (CT26-OxR) cells were induced with 20 ng/mL oxaliplatin for approximately 7 months. The viability of the treated cells was detected by a CCK-8 assay. Apoptosis was determined via flow cytometry. The mRNA and protein expression levels of resistance-related genes were assessed via qRT‒PCR and western blotting (WB), respectively. P-gp expression in HCT116-OxR and HCT116-OxR-miR-506 cells was determined by immunofluorescence (IF) staining. The expression of WNT/β-catenin pathway molecules was determined by qRT‒PCR and WB. The targeted effect of miR-340 on PDCD4 was detected by a Gaussia luciferase secretion assay. miR-340 is downregulated in HCT116-OxR and CT26-OxR cells. Intriguingly, forced expression of miR-340 led to reduced viability in HCT116-OxR and CT26-OxR cells. Furthermore, the upregulation of miR-340 enhanced apoptosis but mitigated the migratory and invasive potential of HCT116-OxR cells. Additionally, miR-340 inhibited the mRNA and protein levels of Bcl-2 while increasing the expression of BAX in HCT116-OxR cells. miR-340 also downregulated the expression of resistance-associated genes and proteins in HCT116-OxR cells. Upon exploring the underlying mechanism further, we discovered that miR-340 also inhibited key components of the WNT/β-catenin signalling pathway, such as WNT5a, WNT5b, β-catenin, c-Myc, and cyclin D1, in HCT116-OxR cells. These findings suggest that miR-340 contributes to overcoming oxaliplatin resistance in CRC, at least partially through downregulation of the WNT/β-catenin pathway. Moreover, miR-340 directly targeted PDCD4 and promoted its transcription. In summary, our findings underscore the potential of miR-340 as a modulator of oxaliplatin resistance in CRC by suppressing the PDCD4/WNT/β-catenin signalling pathway, thereby offering new insights into therapeutic strategies aimed at improving the efficacy of chemotherapy in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.